Axcella Health Inc

Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axcella is a clinical-stage biotechnology company that treats complex diseases using endogenous metabolic modulator (EMM) compositions. They combine biological pathways with developments in systems biology and machine learning. Their proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative, and liver conditions.

Axcella Health Inc. (AXLA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Axcella Health Inc. (AXLA) Loses 47.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Axcella Health Inc. (NASDAQ:AXLA ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Bill Hinshaw - President & CEO Bob Crane - CFO Margaret Koziel - CMO Conference Call Participants Thomas Yip - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Axcella's third quarter 2022 conference call.

Axcella Health Inc. (AXLA) Q3 2022 Earnings Call Transcript

Axcella Reports Third Quarter Financial Results and Provides Business Update

Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022

Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members

Shares of Axcella Therapeutics Inc. AXLA, +6.79% gained 10.9% in premarket trading on Thursday after the biotech said its experimental treatment for nonalcoholic steatohepatitis (NASH) showed statistically significant improvement in liver stiffness at 24 weeks. The Phase 2b trial is ongoing.

Axcella's stock is up 10% after sharing new data for its NASH treatment

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today reported interim results from their ongoing global Phase 2b randomized, double-blind, placebo-controlled, dose ranging EMMPACT study to evaluate the safety, tolerability, and efficacy of AXA1125 for the treatment of NASH. These interim results report finding

Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place September 12 – 14, 2022 both virtually and in-person in New York City. Details for the fireside chat are as

Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Absci Corp

DiCE Molecules Holding LLC

Freeline Therapeutics Holdings

 Pliant Therapeutics

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today reported topline results from the Phase 2a randomized, double-blind, placebo-controlled investigation to evaluate the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID. Long COVID is a persistent and growing challenge of the

Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID

Axcella (AXLA) re-prioritizes its clinical portfolio to focus on the development of AXA1125 targeting long COVID and NASH. It also suspends the development of AXA1665 to focus resources on AXA1125 studies.

Axcella (AXLA) Up on Decision to Prioritize Long-COVID Program

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has prioritized its clinical development portfolio after rapid enrollment for its Phase 2a clinical trial in Long COVID. The company affirmed topline data readout for its Phase 2a Long COVID trial in early Q3 2022 and interim data readout f

Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio

Axcella Health Inc. (AXLA) CEO Bill Hinshaw on Q4 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update. “The year 2021 was one of significant accomplishment for Axcella Therapeutics that was highlighted by the initiation of three distinct Ph

Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its fourth quarter and year end 2021 financial results and other business updates on March 30, 2022. The company will host a conference call at 8:30 a.m. ET that morning. The conference call webcast will be available in the

Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022

Desktop Metal

Martin Midstream Partners

The US Federal Reserve, on Wednesday, raised its target fed funds rate by 0.25%, its first interest rate hike since 2018. Investors, meanwhile, focused on some notable insider trades When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

Insiders Buy Over $7M Of 3 Penny Stocks

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 13,089,002 shares of common stock (the “Shares”) at a purchase price of $1.91 per share, resulting in gross proceeds of $25.0 million. The of

Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market

Axcella Therapeutics (Nasdaq: AXLA) announced that the FDA has granted a Fast Track Designation to AXA1125. These are the details.

Axcella (AXLA) Announces Fast Track Designation For AXA1125

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that the U.S. Food and Drug Administration (FDA) has granted a Fast Track Designation to AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. AXA1125 is a multi-targeted oral drug candidate that is currently being

Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that company management will be participating in the SVB Leerink Global Healthcare Conference. A live webcast of the company's fireside chat from this event will be available on the “Investors & News” section of the Axcella's website, www.axcel

Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced the appointment of Robert Crane as the company's new Chief Financial Officer. “Bob brings a wealth of life sciences experience to Axcella at an important and exciting juncture in the company's evolution,” said Axcella President and Chief Executive

Axcella Therapeutics Announces Appointment of New Chief Financial Officer

Axcella Health Inc. (AXLA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Axcella Health Inc. (AXLA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today outlined key clinical and operational milestones that are expected for the company in 2022. “The year 2021 was a foundational time for Axcella Therapeutics that was highlighted by the clearance of our first investigational new drug (IND) filings and the init

Axcella Therapeutics Details Clinical and Operational Milestones for 2022

News for Axcella Health Inc Stock (AXLA)